Is REGN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

2,378 people get REGN articles and Market Currents by email alert.

Get email alerts on REGN »

HEADLINES:

S&P 500 Stocks Farthest Above 50-DMAs
Bespoke Investment Group • Thu, May 16
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)

PR Newswire (Wed, 1:00AM)
Is Regeneron A Value Pick In The Pharma Sector?
Emerging Equities • Mon, May 13 • 2 Comments
Nailing Big Winners In The Market
Bill Gunderson • Thu, May 9 • 3 Comments
Regeneron Announces Upcoming 2013 Investor Conference Presentations

PR Newswire (May 8, 2013)
Regeneron: Solid Q1 Creates Platform For Further Upside
PropThink • Tue, May 7
How Regeneron's Eylea Became A 'Trump Card' In The Niche AMD Market
Brian L. Wilson • Mon, May 6 • 1 Comment
Cramer's Mad Money - 10 Things To Watch In The Week Ahead (5/3/13)
SA Editor Miriam Metzinger • Sun, May 5 • 4 Comments
Regeneron Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Fri, May 3 • 1 Comment
Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs

PR Newswire (May 3, 2013)
Regeneron Reports First Quarter 2013 Financial and Operating Results

PR Newswire (May 3, 2013)
Cramer's Mad Money - Pharmas Live Or Die By The Pipeline (5/1/13)
SA Editor Miriam Metzinger • Thu, May 2
My Number One Ranked Stock
Bill Gunderson • Fri, Apr 26 • 6 Comments
Regeneron Announces Upcoming 2013 Investor Conference Presentations

PR Newswire (Apr 18, 2013)
Cramer's Mad Money - Analysts Keep Beating Dead Horses (4/17/13)
SA Editor Miriam Metzinger • Thu, Apr 18 • 1 Comment
Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013

PR Newswire (Apr 11, 2013)
The 9 Levels Of Healthcare / Biotechnology And Who Should Invest - Part 1
Brian Nichols • Fri, Apr 5 • 4 Comments
Regeneron Pharmaceuticals Announces Expansion in New York's Hudson Valley

PR Newswire (Apr 4, 2013)
Lucrative AMD And DME Markets Attract Wall Street To Regeneron And Other Players
Brian L. Wilson • Wed, Apr 3 • 3 Comments
Significant Short Interest Decreases (Mid-March Update)
Bill Maurer • Wed, Apr 3 • 2 Comments

To learn more about Seeking Alpha Pro, click here.

Is Regeneron A Value Pick In The Pharma Sector?
Emerging Equities • Mon, May 13 • 2 Comments
Regeneron: Solid Q1 Creates Platform For Further Upside
PropThink • Tue, May 7
How Regeneron's Eylea Became A 'Trump Card' In The Niche AMD Market
Brian L. Wilson • Mon, May 6 • 1 Comment
My Number One Ranked Stock
Bill Gunderson • Fri, Apr 26 • 6 Comments
Lucrative AMD And DME Markets Attract Wall Street To Regeneron And Other Players
Brian L. Wilson • Wed, Apr 3 • 3 Comments
Regeneron: An Evaluation, Heading Into 2013
Brian L. Wilson • Tue, Dec 18, 2012 • 2 Comments
Can Regeneron Continue To Generate Profits?
PropThink • Mon, Dec 17, 2012 • 2 Comments
Regeneron Moves Aggressively On The Potential Behind 2 Drugs
Brian L. Wilson • Tue, Nov 20, 2012 • 2 Comments
A Fast Growing BioPharma Stock To Buy On The Next Pull Back
Bret Jensen • Tue, Nov 13, 2012 • 7 Comments
Why Regeneron Should Benefit From Money Flows Exiting Big-Cap Tech
Inflection Point Investing LLC • Tue, Oct 23, 2012
Regeneron Pharmaceuticals: A Biotech Heading To $200
Drug Dates • Wed, Sep 19, 2012 • 4 Comments
Regeneron's Success Isn't Limited To Eylea
Todd Campbell • Thu, Jul 26, 2012 • 2 Comments
Can Regeneron Continue To Climb? The Pipeline Suggests Yes
Helix Investment Research • Mon, Apr 16, 2012 • 1 Comment
Regeneron: The Best Pipeline In Biotech?
Dana Blankenhorn • Thu, Mar 22, 2012 • 9 Comments
Regeneron Finally Makes It To The Market
Derek Lowe • Tue, Nov 22, 2011 • 2 Comments
Regeneron Hits 20-Year High As Competing Eye Drug Dropped By Dept. Of Veterans Affairs
Kapitall • Thu, Sep 22, 2011
Regeneron: A Great Lesson to Learn
Prohost Biotech • Wed, Apr 27, 2011 • 2 Comments
Regeneron: A Well-Executed Strategy
Prohost Biotech • Tue, Feb 22, 2011 • 5 Comments
Are Regeneron's Gout Drug Trial Results Really Bad News?
Prohost Biotech • Sun, Jun 13, 2010 • 2 Comments
Keep Your Eye on Regeneron Pharmaceuticals
Jerry Helzner • Thu, Sep 6, 2007

S&P 500 Stocks Farthest Above 50-DMAs
Bespoke Investment Group • Thu, May 16
Nailing Big Winners In The Market
Bill Gunderson • Thu, May 9 • 3 Comments
Cramer's Mad Money - 10 Things To Watch In The Week Ahead (5/3/13)
SA Editor Miriam Metzinger • Sun, May 5 • 4 Comments
Cramer's Mad Money - Pharmas Live Or Die By The Pipeline (5/1/13)
SA Editor Miriam Metzinger • Thu, May 2
Cramer's Mad Money - Analysts Keep Beating Dead Horses (4/17/13)
SA Editor Miriam Metzinger • Thu, Apr 18 • 1 Comment
The 9 Levels Of Healthcare / Biotechnology And Who Should Invest - Part 1
Brian Nichols • Fri, Apr 5 • 4 Comments
Significant Short Interest Decreases (Mid-March Update)
Bill Maurer • Wed, Apr 3 • 2 Comments
Check Out These Sectors For Q2 Upside
Todd Campbell • Tue, Apr 2 • 4 Comments
Cramer's Mad Money - 8 Things To Watch Next Week (3/28/13)
SA Editor Miriam Metzinger • Fri, Mar 29 • 3 Comments
Cramer's Mad Money - 12 Things To Watch In The Week Ahead (3/15/13)
SA Editor Miriam Metzinger • Sun, Mar 17 • 7 Comments
5 Names With Drops In Short Interest
Bill Maurer • Wed, Mar 13 • 2 Comments
Growing Pains: Pacira Stretched Very Thin Following Exparel Launch
Richard Pearson • Wed, Mar 13 • 6 Comments
Ohr Pharma: Under The Radar Company With Upcoming Catalysts, Potential For Significant Pay-Off
PropThink • Mon, Mar 11 • 1 Comment
China Biotech Week In Review: Regeneron Pharma, Bayer Start New Trial For DME Treatment
ChinaBio Today • Sun, Feb 24
After The Twists And Turns, Sanofi Still A Value
Stephen Simpson • Tue, Feb 12 • 7 Comments
Biotech Proper Is Overbought, Time To Look At Alternatives
Austrolib • Mon, Feb 4 • 6 Comments
Cramer's Mad Money - What To Do About Dell (1/15/13)
SA Editor Miriam Metzinger • Wed, Jan 16 • 5 Comments
3 Biotech Growth Stocks Near Highs
ONeil Trader • Sat, Jan 12 • 2 Comments
Cramer's Mad Money - The Unsinkable Biogen IDEC (1/8/13)
SA Editor Miriam Metzinger • Wed, Jan 9 • 11 Comments
Cramer's Lightning Round - No One Is Worried About Walgreen (1/2/13)
SA Editor Miriam Metzinger • Thu, Jan 3 • 3 Comments

Regeneron Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Fri, May 3 • 1 Comment
Regeneron Pharmaceuticals' CEO Presents at Barclays Global Healthcare Conference (Transcript)
Tue, Mar 12
Regeneron Pharmaceuticals' Management Presents at Citi 2013 Global Healthcare Conference (Transcript)
Tue, Feb 26
Regeneron Pharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 14
Regeneron Pharmaceuticals' CEO Presents at Credit Suisse Healthcare Conference (Transcript)
Wed, Nov 14, 2012
Regeneron Pharmaceuticals CEO Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Oct 24, 2012
Regeneron Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Wed, Jul 25, 2012 • 1 Comment
Regeneron Pharmaceuticals' CEO Discusses Q1 2012 Results - Earnings Call Transcript
Thu, Apr 26, 2012
Regeneron Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Mon, Feb 13, 2012
Regeneron Pharmaceuticals' CEO Presents at the JPMorgan Global Healthcare Conference (Transcript)
Mon, Jan 9, 2012
Regeneron Pharmaceuticals' CEO Presents at the 2011 Deutsche Bank BioFEST - Conference Call Transcript
Mon, Dec 5, 2011 • 1 Comment
Regeneron Pharmaceuticals Management Hosts Credit Suisse Annual Healthcare Conference - Conference Call Transcript
Wed, Nov 9, 2011 • 1 Comment

Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)

PR Newswire (Wed, 1:00AM)
Jim Cramer's 5 Investing Sweet Spots

at CNBC.com (Tue, 6:00PM)
Regeneron Announces Upcoming 2013 Investor Conference Presentations

PR Newswire (May 8, 2013)
Movers & Shakers: Friday’s movers: Regeneron, LinkedIn

at MarketWatch.com (May 3, 2013)
Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs

PR Newswire (May 3, 2013)
Regeneron Reports First Quarter 2013 Financial and Operating Results

PR Newswire (May 3, 2013)
Jim Cramer: Common Drug Stock Mistake

at CNBC.com (May 1, 2013)
Midday Movers: H, AMT, ICE & More

at CNBC.com (May 1, 2013)
Early Movers: XOM, MMM, UPS & More

at CNBC.com (Apr 25, 2013)
After-Hours Buzz: QCOM, ZNGA, AKAM & More

at CNBC.com (Apr 24, 2013)
Regeneron Announces Upcoming 2013 Investor Conference Presentations

PR Newswire (Apr 18, 2013)
Jim Cramer: Can These Companies 'Do No Wrong'

at CNBC.com (Apr 17, 2013)
Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013

PR Newswire (Apr 11, 2013)
Regeneron Pharmaceuticals Announces Expansion in New York's Hudson Valley

PR Newswire (Apr 4, 2013)
Cramer: This Growth Story Is Far From Over

at CNBC.com (Mar 28, 2013)
Cramer: 8 Top Performers Over Last 8 Years

at CNBC.com (Mar 15, 2013)
Regeneron Announces Potential Additional Royalty Stream Related to EU Approval for Ilaris® (canakinumab) in Patients Suffering Acute Gouty Arthritis Attacks Who Cannot Gain Relief From Current Treatments

PR Newswire (Mar 4, 2013)
Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis

PR Newswire (Mar 2, 2013)
Europe Markets: Europe stocks rally as German ZEW index posts rise

at MarketWatch.com (Feb 19, 2013)
Regeneron Announces Upcoming 2013 Investor Conference Presentations

PR Newswire (Feb 19, 2013)

REGN vs. ETF Alternatives

Company Description

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. We currently have one marketed product: ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 1:49 PM Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%. 1 Comment [Healthcare, On the Move]
Wednesday, May 15, 3:10 PM Regeneron Pharmaceuticals (REGN -3.2%) and Sanofi (SNY -0.7%) have enrolled the first patients for trials of sarilumab, an injection to treat moderate-to-severe rheumatoid arthritis patients who are inadequate responders to either methotrexate or tumor necrosis factor alpha inhibitor therapy. Comment! [Healthcare, Global & FX]
Monday, May 6, 3:27 PM Appearing a bit late to the party, Jefferies raises its price target on Regeneron Pharmaceuticals (REGN -1.3%) to $247 from $179 citing the company's top line, EYLEA sales-driven earnings beat. Jefferies is responding to REGN's hike of FY13 EYLEA sales estimates — the company pointed to a strong ex-U.S. rollout. Q1 sales of the macular degeneration injection were $314M compared to $124M in Q1 2012. 1 Comment [Healthcare]
Friday, May 3, 7:35 AM More on Regeneron's (REGN) Q1 : The company exhibits "sustained revenue and earnings growth" helped by strong EYLEA sales growth in the U.S. (FY13 U.S. sales estimates for the macular degeneration injection hiked to $1.25-1.325B) and a healthy roll out of the drug outside the country by partner Bayer Healthcare. Late stage pipeline makes progress. Shares +5% premarket. ( PR ) Comment! [Healthcare, Earnings, On the Move]
Friday, May 3, 7:04 AM Regeneron Pharmaceuticals (REGN): Q1 EPS of $1.78 beats by $0.37. Revenue of $440M beats by $15.74M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, May 3, 12:05 AM Notable earnings before Friday’s open: ADP, AXL, BBEP, BPL, CBOE, DUK, FBN, GBDC, GTXI, HST, LNT, MCO, NGLS, NRF, NVE, NWL, PNW, POM, PPC, REGN, SE, SEP, SMP, UPL, WCG, XLS, YRCW Comment! [Earnings]
Thursday, May 2, 5:30 PM Notable earnings before Friday’s open: ADP, AXL, BBEP, BPL, CBOE, DUK, FBN, GBDC, GTXI, HST, LNT, MCO, NGLS, NRF, NVE, NWL, PNW, POM, PPC, REGN, SE, SEP, SMP, UPL, WCG, XLS, YRCW Comment! [Earnings]
Wednesday, May 1, 12:50 PM Midday top 10 gainers: IQNT +60%. BCOV +31%. CNIT +28%. MNOV +21%. MSPD +19%. SONS +15%. TRLA +15%. RATE +15%. REGN +14%. SGI +14%.
Midday top 10 losers: ACCL -21%. RBC -20%. ESBF -17%. LEDS -16%. KFRC -15%. AGN -14%. CRAY -13%. ASTX -13%. XXIA -13%. UTI -12%. Comment! [On the Move]
Wednesday, May 1, 11:23 AM Allergan (AGN -9.4%) dives as management - on today's earnings call - has less than great progress to report on a couple of drugs in development. Regeneron (REGN +12.4%) spikes higher. 1 Comment [Healthcare, Breaking News, On the Move]
Wednesday, May 1, 10:36 AM Goldman raises its price target on Regeneron Pharmaceuticals (REGN +3%) to $240 from $230 after a survey of 41 U.S.-based cardiologists/lipidologists shows awareness of anti-PCSK9 drugs is widespread and "physicians project to use this class of drugs in 25-50% of their patients one year after approval." Putting it all together, Goldman hikes its peak sales estimates for REGN727 (developed with Sanofi SNY) to $3.5B from $3B and says it expects the company to report Phase III data in Q3. (Previoulsly: GS reiterates Buy on REGN) Comment! [Healthcare, On the Move]
Wednesday, April 24, 5:46 PM S&P announces some changes to its index lineup today: Regeneron Pharmaceuticals (REGN) will join the S&P 500, replacing MetroPCS (PCS) which is being acquired by T-Mobile USA. S&P SmallCap 600 constituent Eagle Materials (EXP) will replace REGN in the S&P MidCap 400, and Francesca's Holdings (FRAN) will replace Eagle Materials in the S&P SmallCap 600 after the close of trading on Tuesday, April 30. 1 Comment [Healthcare, Tech, Commodities, Consumer]
Tuesday, April 9, 11:33 AM Regeneron (REGN +1.7%) gets a lift today as Goldman reiterates its Buy recommendation and raises its price target on the shares to $215 from $196 citing relative YTD underperformance versus the Nasdaq Biotech index and a strong Eylea launch. Comment! [Healthcare, On the Move]
Thursday, February 14, 8:23 AM More on Regeneron Pharma (REGN +1.6%) Q4: swings to net profit of $470M from a net loss of $53.4M as sales more than triple, with its Eylea eyecare product bringing in $276M. Earnings also include $127M in collaboration revenues and a non-cash tax benefit of $336M. Forecasts 2013 Eyelea sales of $1.2-1.3B in the U.S. Partner Bayer has started to launch the product overseas. (PR) 1 Comment [Earnings, Healthcare]
Thursday, February 14, 6:32 AM Regeneron Pharma (REGN): Q4 EPS of $1.47 beats by $0.23. Revenue of $415M beats by $22.36M. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
Thursday, February 14, 12:05 AM Notable earnings before Thursday’s open: ABB, ABX, ALXN, ANR, APA, BGCP, BWA, CAB, CRIS, CVE, DISCA, DTV, DVA, DWRE, ECA, GELG, GM, GNC, GNRC, INCY, JAH, LNT, LUFK, MFA, NGLS, NRF, O, OAK, PDS, PEP, PPL, REGN, SHPG, STRA, TAP, UTHR, VMC, WM, ZIP Comment! [Earnings]
Wednesday, February 13, 5:30 PM Notable earnings before Thursday’s open: ABB, ABX, ALXN, ANR, APA, BGCP, BWA, CAB, CRIS, CVE, DISCA, DTV, DVA, DWRE, ECA, GELG, GM, GNC, GNRC, INCY, JAH, LNT, LUFK, MFA, NGLS, NRF, O, OAK, PDS, PEP, PPL, REGN, SHPG, STRA, TAP, UTHR, VMC, WM, ZIP Comment! [Earnings]

Capitalist Bull
Leading growth stocks taking a break while the $ES_F shows no signs of fatigue. http://stks.co/qD73 $NFLX $REGN $SPWR $GOOG $CELG $NSM
Thu, 2:22 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chines33
Oh my $REGN
May 1, 11:38 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ONeil Trader
$REGN strong today, near all time highs
Apr 2, 1:55 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
Returning Upgrades (3/28/13): $MORN, $NBL, $NE, $NOW, $NPO, $NSC, $OTEX, $QLD, $REGN, $RHP, $RUE, $SLH, $SPY, $TDY, $THOR, $THRX, $TQQQ
Apr 1, 9:11 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
LinkedIn ($LNKD), H. B. Fuller ($FUL), Regeneron Pharma ($REGN), Ruckus Wireless ($RKUS), & Fossil ($FOSL) rose Monday on unusual volume.
Feb 11, 10:58 PM
Reply (1)

• !Report Abuse
View all 1 replies
Closet Iguana: I wouldn't hold $FOSL much longer
Feb 12, 12:27 PM
• !Report Abuse
Add a reply...

140 characters

Jason F
If You Are Bullish, here are a few long stock ideas. http://bit.ly/T84cxe $SPY $SPX $DIA $LNKD $NSR $BIIB $REGN
12/21/12
Reply (3)

• !Report Abuse
View all 3 replies
FortSumter: an appointment in the Obama administration. Renewal, that is. Thanks for the list.
12/22/12
• !Report Abuse
Jason F: np
12/22/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Regeneron Pharma ($REGN), Bonanza ($BCEI), Manhattan ($MANH), Portfolio Recovery ($PRAA), & Watson Pharma ($ACT) rose Friday on unusual vol.
12/21/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Brian L. Wilson
$CELG $MDVN $ONXX $REGN $TLON.OB - 5 companies with newly approved cancer drugs to watch next year http://seekingalpha.com/a/mc3t
12/3/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
PAREXEL ($PRXL), Kroger ($KR), Regeneron Pharmaceuticals ($REGN), HDFC Bank ($HDB), & SouFun ($SFUN) rose Thursday on unusual volume.
11/30/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
American Woodmark ($AMWD), Team ($TISI), Qihoo 360 ($QIHU), Regeneron Pharma ($REGN), & Sturm, Ruger ($RGR) rose Tuesday on unusual volume.
11/21/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Michael Bryant
LinkedIn ($LNKD), H. B. Fuller ($FUL), Regeneron Pharma ($REGN), Ruckus Wireless ($RKUS), & Fossil ($FOSL) rose Monday on unusual volume.
Feb 11, 10:58 PM
Reply (1)

• !Report Abuse
View all 1 replies
Closet Iguana: I wouldn't hold $FOSL much longer
Feb 12, 12:27 PM
• !Report Abuse
Add a reply...

140 characters

Jason F
If You Are Bullish, here are a few long stock ideas. http://bit.ly/T84cxe $SPY $SPX $DIA $LNKD $NSR $BIIB $REGN
12/21/12
Reply (3)

• !Report Abuse
View all 3 replies
FortSumter: an appointment in the Obama administration. Renewal, that is. Thanks for the list.
12/22/12
• !Report Abuse
Jason F: np
12/22/12
• !Report Abuse
Add a reply...

140 characters

Jim Van Meerten
REGN - 100% Barchart technical buy signal - 4 new highs and up 5.07% in the last month - Relative Strength Index 66.77%
10/2/12
Reply (3)

• !Report Abuse
View all 3 replies
Jim Van Meerten: That's why I use a moving stop loss
10/2/12
• !Report Abuse
David White: OK. Good luck.
10/2/12
• !Report Abuse
Add a reply...

140 characters

Capitalist Bull
Traditional Technical Patterns completing & readying to #Breakout..$AAPL $GOOG $CLMT $REGN $RYL $BIDU $ALXN $ACT & more http://bit.ly/MwUXlb
8/15/12
Reply (1)

• !Report Abuse
View all 1 replies
Ocean Man: Thought about buying CLMT this morning. Oops.
8/15/12
• !Report Abuse
Add a reply...

140 characters

Capitalist Bull
#LeadingStocks Up on #Volume: $STX $EQIX $MLNX $SWI $SPF $REGN $PII $FIRE $UTHR $IACI $BIDU $DHI $CRUS $LKQ $NSR $PCLN http://bit.ly/MwUXlb
7/26/12
Reply (3)

• !Report Abuse
View all 3 replies
Capitalist Bull: These are the stocks you want to pay attention to for possible setups in the near future.
7/28/12
• !Report Abuse
Day Trader001: I get Volume alerts sent to me directly, I guess I just didn't get why you posted them. Thought I was missing something. Thanks
7/28/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://stks.co/3Wb3 Premarket losers $FURX $TQNT $TSPT $HERO $AKAM $CROX $CELG $MPEL Gainers $PATK $HTWR $LOGI $REGN $CTXS $SPPI $EQIX $CRUS
4/26/12
Reply (5)

• !Report Abuse
View all 5 replies
Maria Auziliadora: Good job
4/26/12
• !Report Abuse
Maria Auziliadora: That stock will come back though that's m feeling maybe not today!!!
4/26/12
• !Report Abuse
Add a reply...

140 characters

REGN Regeneron Pharmaceuticals, Inc.

REGN

Regeneron Pharmaceuticals, Inc.